Standpoint Research Upgrades Hi Tech Pharmacal (HITK) to Buy
Tweet Send to a Friend
Standpoint Research upgraded Hi Tech Pharmacal (NASDAQ: HITK) from Hold to Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE